Stockscreener 앱 받기
30.17
1.35%
0.32
전일 마감가:
$29.85
열려 있는:
$30.22
하루 거래량:
493.25K
Relative Volume:
0.41
시가총액:
$2.49B
수익:
-
순이익/손실:
$-154.65M
주가수익비율:
-12.68
EPS:
-2.3786
순현금흐름:
$-142.43M
1주 성능:
+16.23%
1개월 성능:
+9.98%
6개월 성능:
-30.23%
1년 성능:
+89.56%
1일 변동 폭
$30.00
$30.74
1주일 범위
$26.50
$30.74
52주 변동 폭
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
30.20 | 2.46B | 0 | -154.65M | -142.43M | -2.3786 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.12 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.56 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | TD Cowen | Buy |
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Technical Reactions to MLYS Trends in Macro Strategies - Stock Traders Daily
Mineralys Therapeutics shareholders approve director elections and auditor at annual meeting - Investing.com Canada
Mineralys Therapeutics (MLYS) 2026 meeting approves directors and auditor - Stock Titan
Mineralys Therapeutics Stock Surges on Trial Hopes - TipRanks
Mineralys CMO David Rodman sells $11,488 in shares By Investing.com - Investing.com Canada
Mineralys CMO David Rodman sells $11,488 in shares - Investing.com
Mineralys (NASDAQ: MLYS) CMO exercises options and sells 417 pre-planned shares - Stock Titan
Guggenheim Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $48 - Moomoo
417‑share proposed sale by Mineralys (NASDAQ: MLYS) via cashless exercise - Stock Titan
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) - The Manila Times
Mineralys Therapeutics announces presentation of new data from the late-stage launch-htn trial of lorundrostat - marketscreener.com
Mineralys Therapeutics Announces Presentation Of New Data From The Late-Stage Launch-Htn Trial Of Lorundrostat - TradingView
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $42 to $56 - Moomoo
Why Mineralys Therapeutics Stock Is Sinking Today - TipRanks
Mineralys Advances Hypertension Drug Toward FDA Decision - MyChesCo
Mineralys Therapeutics (Nasdaq: MLYS) Grants Equity Awards to New Hires - MyChesCo
Mineralys Therapeutics Insider Sold Shares Worth $652,638, According to a Recent SEC Filing - Moomoo
Trading the Move, Not the Narrative: (MLYS) Edition - Stock Traders Daily
Mineralys CMO Rodman sells $652,637 in company stock By Investing.com - Investing.com Australia
David Malcom Rodman Sells 2,171 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys CMO Rodman sells $652,637 in company stock - Investing.com UK
Mineralys (NASDAQ: MLYS) CMO exercises options, sells 22,575 shares in 10b5-1 plan - Stock Titan
Multiple affiliate sales and option exercises at Mineralys Therapeutics (MLYS) - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Vanguard Group Inc. - MarketBeat
Mineralys (MLYS) Q1 2026 Earnings Transcript - AOL.com
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
MLYS: Lorundrostat advances toward FDA approval with strong clinical data and launch readiness - TradingView
MLYS: NDA accepted for lorundrostat; launch prep and strong cash position support U.S. commercialization - TradingView
TradingKey - TradingKey
How FDA NDA Acceptance for Lorundrostat At Mineralys Therapeutics (MLYS) Has Changed Its Investment Story - Yahoo Finance
HC Wainwright Issues Pessimistic Forecast for MLYS Earnings - MarketBeat
Mineralys outlines lorundrostat US launch plans ahead of December 22, 2026 PDUFA - MSN
Mineralys Therapeutics, Inc. $MLYS Stock Holdings Lessened by Swedbank AB - MarketBeat
LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $54 - Moomoo
H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Mineralys Therapeutics Maps Path After Lorundrostat NDA - TipRanks
Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move - Seeking Alpha
Mineralys Therapeutics, Inc. Q1 2026 Financials: Lorundrostat Clinical Progress and Key SEC Filings - Minichart
Mineralys Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Mineralys Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Mineralys Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
MLYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings call transcript: Mineralys Therapeutics beats Q1 2026 EPS estimates By Investing.com - Investing.com Australia
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mineralys Therapeutics Inc 주식 (MLYS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
May 18 '26 |
Sale |
27.55 |
417 |
11,488 |
63,443 |
2.25%
0.46%
자본화:
|
볼륨(24시간):